Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
Status:
Withdrawn
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
In an unbiased metabolomics approach with subsequent pathway analyses, the current study
seeks to examine the effect of Liraglutide treatment on the metabolic signature in treated
patients as well as the effect of Liraglutide on various echocardiographic parameters of
cardiac function and rhythm profile, thus paving the way for future research to explain the
effects of Liraglutide on cardiovascular mortality and overall mortality in treated patients.